PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable ® ’ disease targets, today announced it has relocated its headquarters to Unity Campus, a high ...

CAMBRIDGE, England, May 21, 2024--PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™. The new ...

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, announces the appointment of Dr Adam ...

PhoreMost Ltd (PhoreMost) has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. The groups will study and translate essential ...

CAMBRIDGE, England-- (BUSINESS WIRE)--PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim.

CAMBRIDGE, England--(BUSINESS WIRE)--PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a structural ...

PhoreMost Ltd (PhoreMost), a biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, has entered into a research collaboration with the laboratory of Professor David Rubinsztein ...

CAMBRIDGE, Mass., March 23, 2021 /PRNewswire/ -- XtalPi, an artificial intelligence (AI) drug discovery and development company, is pleased to announce its investment in the Series B financing of ...

The funding will enable PhoreMost to expand the range and depth of other proprietary targets into the drug discovery process. The Series-A round was led by current investors Jonathan Milner, Amadeus ...

DURHAM, N.C. and CAMBRIDGE, England, Jan. 5, 2022 /PRNewswire/ -- Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, and PhoreMost Limited, a UK-based ...

LONDON – "Drugging the undruggable" is the bold claim newco Phoremost Ltd. is making for its technology. The Cambridge University spinout said it can systematically identify and access intracellular ...